As Of September 30, 2024 Autonomix Medical Had Cash Of $5.2M
As Of September 30, 2024 Autonomix Medical Had Cash Of $5.2M
Research and development expense was $1.2 million for the three months ended September 30, 2024 compared to $0.5 million for the same period in 2023. The increase in research and development expenses during the current quarter was mainly attributed to our clinical trial and product development costs.Summary of Financial Results for Three and Six Months Ended September 30, 2024
截至2024年9月30日的三個月和六個月的財務業績摘要
For the three months ended September 30, 2024 and 2023, the Company incurred net losses of $2.8 million and $6.0 million, respectively.
在截至2024年9月30日和2023年9月30日的三個月中，該公司的淨虧損分別爲280萬美元和600萬美元。
General and administrative expense was $1.7 million for the three months ended September 30, 2024 compared to $0.8 million for the same period in 2023. This $0.9 million increase was driven primarily by increases in officer and employee compensation and benefits of $0.4 million, as we expanded our management team, stock-based compensation of $0.2 million, insurance expense of $0.1 million, franchise tax of $0.1 million, and other expenses of $0.1 million.
截至2024年9月30日的三個月，一般和管理費用爲170萬美元，而2023年同期爲80萬美元。這90萬美元的增長主要是由管理團隊擴大後高管和員工薪酬和福利增加了40萬美元，股票薪酬增加了20萬美元，保險費用爲10萬美元，特許經營稅增加了10萬美元，其他支出爲10萬美元。
Research and development expense was $1.2 million for the three months ended September 30, 2024 compared to $0.5 million for the same period in 2023. The increase in research and development expenses during the current quarter was mainly attributed to our clinical trial and product development costs.
截至2024年9月30日的三個月，研發費用爲120萬美元，而2023年同期爲50萬美元。本季度研發費用的增加主要歸因於我們的臨床試驗和產品開發成本。
For the six months ended September 30, 2024 and 2023, the Company incurred net losses of $5.5 million and $6.9 million, respectively.
在截至2024年9月30日和2023年9月30日的六個月中，該公司的淨虧損分別爲550萬美元和690萬美元。
General and administrative expense was $3.5 million for the six months ended September 30, 2024 compared to $1.3 million for the same period in 2023. This $2.2 million increase was driven primarily by increases in officer and employee compensation and benefits of $1.0 million, as we expanded our management team, stock-based compensation of $0.6 million, legal and professional fees of $0.2 million, insurance expense of $0.2 million, franchise tax of $0.2 million, and board of directors compensation of $0.1 million, offset by a decrease in advertising expense of $0.1 million.
截至2024年9月30日的六個月中，一般和管理費用爲350萬美元，而2023年同期爲130萬美元。220萬澳元的增長主要是由管理團隊擴大後高管和員工薪酬和福利增加了100萬美元，股票薪酬增加了60萬美元，法律和專業費用20萬美元，保險費用20萬美元，特許經營稅20萬美元，董事會薪酬增加10萬美元，被廣告支出減少的10萬美元所抵消。
Research and development expense was $2.1 million for the six months ended September 30, 2024 compared to $0.8 million for the same period in 2023. The increase in research and development expenses during the current year was mainly attributed to our clinical trial and product development costs.
截至2024年9月30日的六個月中，研發費用爲210萬美元，而2023年同期爲80萬美元。本年度研發費用的增加主要歸因於我們的臨床試驗和產品開發成本。
As of September 30, 2024 the Company had cash of $5.2 million.
截至2024年9月30日，該公司的現金爲520萬美元。